MEDFORD, Mass.--(BUSINESS WIRE)--PixarBio Corporation today announced two new members of the Board of Directors. David Cass will serve as an independent member and he’ll join the audit committee as well as the governance and nominating committee. Katrin Holzhaus will join the Board of Directors and serve as Secretary of the Board. In addition, Katrin will be a member of the governance and nominating committee.
PixarBio CEO Frank Reynolds said, “We’ve added two key members to our Board of Directors, in order to establish the necessary credibility and integrity, for a strong shareholder value-driven corporate governance model. We’ll quickly work to become and then remain SEC compliant to be a fully reporting company. We’re entering our next important phase of development as we accelerate our growth plans from Q3 2014 through Q4 2015. We expect to be approved to begin human studies in multiple orphan status neurological conditions in 2016. If luck does favor the prepared mind, then we’ve had an incredibly lucky first year in our PixarBio labs.”
Mr. Cass is the Chief Information Security Officer for Elsevier. Elsevier publishes more than 2,000 journals and 20,000 books. They are a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries. He leads an organization of experienced legal, risk and security professionals that provide data protection, privacy, security, and risk management guidance on a global basis for Elsevier.
David has extensive experience in IT security, risk assessment, risk management, business continuity and disaster recovery, developing security policies and procedures. He has played a key role in leading and building corporate risk & governance and information security organizations in the financial sector. As the Senior Director of Information Security Risk and Governance for Freddie Mac, David rebuilt the risk and governance function and developed a team to provide risk assessments, methodologies, tools, services, and training to improve the maturity and capabilities of Freddie Mac’s information security, risk and governance programs. Prior to that he was Vice President of Risk Management for JPMorgan Chase, and was responsible for providing an accurate assessment of the current risk management state, contributing to the future direction of risk management, continuity and disaster recovery capabilities for the organization. David’s MBA is from The MIT-Sloan School of Business, and he received his Masters of Science in Engineering from Penn Engineering and The Wharton School. David is a Coast Guard licensed Captain and a volunteer firefighter. David married his college sweetheart Julie, and has one daughter Samantha.
“I’ve had the opportunity to meet with the PixarBio team, and it is clear that Mr. Reynolds has assembled a strong team of dedicated and accomplished professionals. I look forward to serving on both the audit and the governance and nominating committees and to being a member of the Board of Directors.”
“I met David as a peer at The Wharton School and I’ve observed David lead his business units at JP Morgan Chase, and Freddie Mac,” said Frank Reynolds. “Now at Elsevier, David has an established track record with the utmost integrity, credibility, and professionalism”. David will serve as a member of the audit and general nominations committee.
Katrin Holzhaus cofounded PixarBio as Chief Operating Officer, leveraging her 20 years of experience as entrepreneur and leader in operations, development, and global marketing. Having worked closely with cofounder Frank Reynolds for more than 14 years initially at Expand the Knowledge, and then with InVivo Therapeutics Holdings Corp (NVIV), Ms. Holzhaus brings complimentary leadership skillsets to PixarBio’s operations team and a proven record of success. Most recently, she held executive positions at InVivo Therapeutics, a developer of groundbreaking technologies for the treatment of spinal cord injuries. From 2004-2012, she was Director of Operations at Magnum Group, Inc., a leading global linguistic consulting company.
“Katrin has been on the front edge of innovative decision making for a long time and brings unique skills to every project she leads for PixarBio. She’ll serve as the Secretary of the Board, and as a member of The Board’s general nominating committee, Katrin will ensure shareholder assets are focused on shareholder value creating initiatives”, says Frank Reynolds. “With our new state-of-the-art chem lab, tissue lab, and bio labs up and running, our expanding team of industry-leading experts is creating value every day. As we plan clinical pathways to market for four fields of medicine, PixarBio is entering an important new phase of development. It is an exciting time to join the company’s Board of Directors and I am thrilled to be part of this outstanding team,” continues Katrin Holzhaus.
Katrin Holzhaus received her MBA and MS in Management Information Systems from Temple University, Philadelphia, Pennsylvania and a Master of Arts in Linguistics from Leipzig University, Germany.
About PixarBio Corporation
PixarBio Corporation is dedicated to developing new therapeutic options for Parkinson’s disease, epilepsy, pain, and spinal cord injury. Cofounded by Frank Reynolds, Dr. Robert S. Langer from MIT’s Langer Lab, Dr. Randy Holmes-Farley, and Katrin Holzhaus the company is developing novel smart materials to achieve sustained release of agents. Research is focused on a platform for chronic neurological applications. For more information visit www.pixarbio.com.